help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mogul, H. R.
Right arrow Articles by Gambert, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mogul, H. R.
Right arrow Articles by Gambert, S. R.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 4492-4495, Copyright © 1996 by Endocrine Society


ARTICLES

Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women

HR Mogul, M Marshall, M Frey, HB Burke, PS Wynn, S Wilker, AL Southern and SR Gambert
Division of Endocrinology and Metabolism, New York Medical College, Valhalla 10595, USA. hrmogul@mem.po.com

Hyperinsulinemia, a manifestation of insulin resistance, precursor of non-insulin dependent diabetes mellitus (NIDDM) and the hallmark of Syndrome X was assessed in 27 obese post-menopausal women. Insulin-like growth factor binding protein-1 (IGFBP-1), which had been shown previously to correlate inversely with insulin in animal and human studies, was evaluated as a diagnostic marker for abnormal glucose stimulated area under the curve (AUC) insulin (defined a priori as > or = 100 microU/ml). We performed analysis of variance and logistic regression to assess IGFBP-1 and other study covariates, including body mass index, blood pressure, lipids and measures of glucose and insulin in hyperinsulinemic vs. normal women and evaluated performance characteristics (sensitivity, specificity, positive and negative predictive values and accuracy rates). The mean IGFBP-1 was 6.1 ng/ml (95% confidence interval (CI) 3.1 to 8.9) for the hyper-insulinemic women compared to 33.5 ng/ml (CI 15.8 to 51.2) for normal women (P = .0027). At a cutoff point of 15ng/ml, which was selected to correspond to the lower 95% confidence limit for the normal study population, IGFBP-1 was abnormal in all 13 women with hyperinsulinemia and 4 women with normal insulin levels (sensitivity 100%, specificity 69%; positive predictive value 76%, negative predictive value 100%, diagnostic accuracy rate 85%). Logistic regression models indicated that, of all study covariates, IGFBP-1 was the best predictor variable for AUC- insulin as a binary dependent variable. These results suggest that IGFBP-1 may be a simple serum marker for hyperinsulinemia in a subpopulation of obese menopausal women.


This article has been cited by other articles:


Home page
Diabetes CareHome page
B. A. Maddux, A. Chan, L. J. Mandarino, I. D. Goldfine, and E. A. De Filippis
IGF-Binding Protein-1 Levels Are Related to Insulin-Mediated Glucose Disposal and Are a Potential Serum Marker of Insulin Resistance
Diabetes Care, July 1, 2006; 29(7): 1535 - 1537.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. H. Saydah, C. M. Loria, M. S. Eberhardt, and F. L. Brancati
Abnormal Glucose Tolerance and the Risk of Cancer Death in the United States
Am. J. Epidemiol., June 15, 2003; 157(12): 1092 - 1100.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. K. Hansen, J. O. L. Jorgensen, and J. S. Christiansen
Body Composition and Circulating Levels of Insulin, Insulin-Like Growth Factor-Binding Protein-1 and Growth Hormone (GH)-Binding Protein Affect the Pharmacokinetics of GH in Adults Independently of Age
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2185 - 2193.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Ruotolo, P. Bavenholm, K. Brismar, S. Efendic, C.-G.o. Ericsson, U. de Faire, J. Nilsson, and A. Hamsten
Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment
J. Am. Coll. Cardiol., March 1, 2000; 35(3): 647 - 654.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. J. H. M. T. van Dessel, P. D. K. Lee, G. Faessen, B. C. J. M. Fauser, and L. C. Giudice
Elevated Serum Levels of Free Insulin-Like Growth Factor I in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3030 - 3035.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice
The Insulin-Related Ovarian Regulatory System in Health and Disease
Endocr. Rev., August 1, 1999; 20(4): 535 - 582.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. H. Travers, J. I. Labarta, S. E. Gargosky, R. G. Rosenfeld, B. W. Jeffers, and R. H. Eckel
Insulin-Like Growth Factor Binding Protein-I Levels Are Strongly Associated with Insulin Sensitivity and Obesity in Early Pubertal Children
J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1935 - 1939.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
M. I. Ndubuisi, K. Patel, R. J. Rayanade, A. Mittelman, L. T. May, and P. B. Sehgal
Distinct Classes of Chaperoned IL-6 in Human Blood: Differential Immunological and Biological Availability
J. Immunol., January 1, 1998; 160(1): 494 - 501.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society